Alan Gary Palestine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alan Gary Palestine has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
Jennifer L. Patnaik
Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, United States
7 shared publicationsPaula E. Pecen
Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO
7 shared publications- Amit K. Reddy
Department of Ophthalmology, University of Colorado School of Medicine, Aurora, USA
6 shared publications - Jennifer Landrigan Patnaik
Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, USA
5 shared publications - Anne M. Lynch
Department of Ophthalmology, University of Colorado School of Medicine, Aurora, Colorado
4 shared publications Daniel J. Ozzello
Department of Ophthalmology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA
4 shared publications
Latest Publications
- 17 September 2026
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (11) , e151-e152
Reply
- 18 May 2026
- Published by Wolters Kluwer Health in Cornea
- Vol. 45 (11) , 1437-1445
Blue Dacryorrhea After Inadvertent Infiltration of the Lacrimal Gland During Scleral Tattooing
Purpose: To report a novel complication of scleral tattooing: inadvertent lacrimal gland infiltration leading to dacryoadenitis and pigmented dacryorrhea. Methods and Results: A case report of a 25-year-old woman who presented to the emergency department with persistent unilateral eye pain, photophobia, and a history of bright blue tears 4 months after undergoing a scleral tattooing procedure. Diagnosis was confirmed via clinical ophthalmological examination and contrast-enhanced orbital computed tomography (CT). Examination revealed teal tattoo pigment within the palpebral lobe of the ipsilateral lacrimal gland, which was enlarged and tender, consistent with dacryoadenitis. Pigment was also noted in the limbal vasculature. Orbital CT confirmed anterior globe pigment deposition without evidence of globe penetration, cellulitis, or abscess. The patient's symptoms resolved with a conservative management strategy of topical antibiotic-steroid drops and lubrication. Conclusions: This case expands the known spectrum of scleral tattoo-related complications to include lacrimal gland involvement and pigmented tearing. It demonstrates that severe adnexal morbidity can occur even in the absence of globe penetration. Ophthalmologists should be aware of this potential complication and carefully examine the lacrimal system in patients with a history of ocular body modification. This report underscores the substantial risks of scleral tattooing and reinforces the need for patient counseling against the procedure.
- 18 May 2026
- Published by Wolters Kluwer Health in Cornea
- Vol. 45 (11) , 1437-1445
Blue Dacryorrhea After Inadvertent Infiltration of the Lacrimal Gland During Scleral Tattooing
Purpose: To report a novel complication of scleral tattooing: inadvertent lacrimal gland infiltration leading to dacryoadenitis and pigmented dacryorrhea. Methods and Results: A case report of a 25-year-old woman who presented to the emergency department with persistent unilateral eye pain, photophobia, and a history of bright blue tears 4 months after undergoing a scleral tattooing procedure. Diagnosis was confirmed via clinical ophthalmological examination and contrast-enhanced orbital computed tomography (CT). Examination revealed teal tattoo pigment within the palpebral lobe of the ipsilateral lacrimal gland, which was enlarged and tender, consistent with dacryoadenitis. Pigment was also noted in the limbal vasculature. Orbital CT confirmed anterior globe pigment deposition without evidence of globe penetration, cellulitis, or abscess. The patient's symptoms resolved with a conservative management strategy of topical antibiotic-steroid drops and lubrication. Conclusions: This case expands the known spectrum of scleral tattoo-related complications to include lacrimal gland involvement and pigmented tearing. It demonstrates that severe adnexal morbidity can occur even in the absence of globe penetration. Ophthalmologists should be aware of this potential complication and carefully examine the lacrimal system in patients with a history of ocular body modification. This report underscores the substantial risks of scleral tattooing and reinforces the need for patient counseling against the procedure.
- Open Access
- 2 January 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 284, 78-87
Dazdotuftide: Novel Treatment for Noninfectious Uveitis with Superior Intraocular Pressure Safety Profile: A Randomized Clinical Trial
- 2 January 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 284, 78-87
Open AccessDazdotuftide: Novel Treatment for Noninfectious Uveitis with Superior Intraocular Pressure Safety Profile: A Randomized Clinical Trial
- 3 April 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 9 (10) , 1005-1016
Guidelines for the Diagnosis, Management, and Study of Autoimmune Retinopathy from the American Academy of Ophthalmology's Task Force
- 3 April 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 9 (10) , 1005-1016
Guidelines for the Diagnosis, Management, and Study of Autoimmune Retinopathy from the American Academy of Ophthalmology's Task Force
- Open Access
- 3 January 2025
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 14 (2) , 461-469
Patient Characteristics, Diagnoses, and Management in a Combined Uveitis–Rheumatology Clinic
Introduction Combined uveitis–rheumatology clinics (combined clinics) are a relatively recent clinical care model. Here we report the demographics, ocular and systemic disease characteristics, and medications utilized in patients seen in a combined clinic at a tertiary care hospital in the USA. Methods Medical records were reviewed of patients seen at the Combined Clinic at the University of Colorado Hospital between January 1, 2016 and November 1, 2023. Data including age, sex, referral indication, ocular and systemic inflammatory disease diagnosis, and therapies utilized were obtained. Results A total of 171 patients were included in the study, of which 122 were diagnosed with a systemic inflammatory disease, the most common of which were spondyloarthritis and rheumatoid arthritis. Nearly half of patients referred to the combined clinic with a known ocular inflammatory disease (OID) and suspicion for a systemic process were eventually diagnosed with a systemic disease. The most common associations in patients with both OID and systemic disease were anterior uveitis with spondyloarthritis, and scleritis with rheumatoid arthritis. The most common systemic immunomodulatory therapies (IMT) used were adalimumab, methotrexate, and rituximab. Over 40% of patients underwent a change in IMT during their first evaluation. Conclusions Most patients seen in the combined clinic had both ocular and systemic inflammatory disease and were treated with IMT. Many patients were diagnosed with a systemic inflammatory disease upon evaluation in the combined clinic, and nearly half were recommended to initiate or change IMT at their first visit. This highlights the utility of a combined clinic in the management of these complex patients, in addition to providing logistical benefits to patients and educational opportunities for trainees.
- 3 January 2025
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 14 (2) , 461-469
Open AccessPatient Characteristics, Diagnoses, and Management in a Combined Uveitis–Rheumatology Clinic
Introduction Combined uveitis–rheumatology clinics (combined clinics) are a relatively recent clinical care model. Here we report the demographics, ocular and systemic disease characteristics, and medications utilized in patients seen in a combined clinic at a tertiary care hospital in the USA. Methods Medical records were reviewed of patients seen at the Combined Clinic at the University of Colorado Hospital between January 1, 2016 and November 1, 2023. Data including age, sex, referral indication, ocular and systemic inflammatory disease diagnosis, and therapies utilized were obtained. Results A total of 171 patients were included in the study, of which 122 were diagnosed with a systemic inflammatory disease, the most common of which were spondyloarthritis and rheumatoid arthritis. Nearly half of patients referred to the combined clinic with a known ocular inflammatory disease (OID) and suspicion for a systemic process were eventually diagnosed with a systemic disease. The most common associations in patients with both OID and systemic disease were anterior uveitis with spondyloarthritis, and scleritis with rheumatoid arthritis. The most common systemic immunomodulatory therapies (IMT) used were adalimumab, methotrexate, and rituximab. Over 40% of patients underwent a change in IMT during their first evaluation. Conclusions Most patients seen in the combined clinic had both ocular and systemic inflammatory disease and were treated with IMT. Many patients were diagnosed with a systemic inflammatory disease upon evaluation in the combined clinic, and nearly half were recommended to initiate or change IMT at their first visit. This highlights the utility of a combined clinic in the management of these complex patients, in addition to providing logistical benefits to patients and educational opportunities for trainees.
- 27 March 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 264, 168-177
Association Between Quantitative and Qualitative Imaging Biomarkers and Geographic Atrophy Growth Rate
- 27 March 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 264, 168-177
Association Between Quantitative and Qualitative Imaging Biomarkers and Geographic Atrophy Growth Rate
- Open Access
- 26 March 2024
- Published by Frontiers Media SA in Frontiers in Ophthalmology
- Vol. 4, 1356957
Elevated tumor necrosis factor alpha and vascular endothelial growth factor in intermediate age-related macular degeneration and geographic atrophy
Introduction: Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine implicated in pathological changes to the retinal pigment epithelium that are similar to changes in geographic atrophy (GA), an advanced form of age related macular degeneration (AMD). TNF-α also modulates expression of other cytokines including vascular endothelial growth factor (VEGF), leading to choroidal atrophy in models of AMD. The purpose of this study was to investigate systemic TNF-α and VEGF in patients with GA and intermediate AMD (iAMD) compared to controls without AMD.Methods: We examined plasma levels of TNF-α and VEGF in patients with GA, iAMD, and controls without AMD from the University of Colorado AMD registry (2014 to 2021). Cases and controls were characterized by multimodal imaging. TNF-α and VEGF were measured via multiplex immunoassay and data were analyzed using a non-parametric rank based linear regression model fit to plasma biomarkers.Results: There were 97 GA, 199 iAMD patients and 139 controls. TNF-α was significantly increased in GA (Median:9.9pg/ml, IQR:7.3-11.8) compared to iAMD (Median:7.4, IQR:5.3-9.1) and in both GA and iAMD compared to controls (Median:6.4, IQR:5.3-7.8), p<0.01 for all comparisons. VEGF was significantly increased in iAMD (Median:8.9, IQR:4.8-14.3) compared to controls (Median:7.7, IQR:4.6-11.1), p<0.01. There was a significant positive correlation between TNF-α and VEGF in GA (0.46, p<0.01), and iAMD (0.20, p=0.01) with no significant interaction between TNF-α and VEGF in any group.Discussion: These findings suggest TNF-α and VEGF may contribute to systemic inflammatory processes associated with iAMD and GA. TNF-α and VEGF may function as systemic biomarkers for disease development.
- 26 March 2024
- Published by Frontiers Media SA in Frontiers in Ophthalmology
- Vol. 4, 1356957
Open AccessElevated tumor necrosis factor alpha and vascular endothelial growth factor in intermediate age-related macular degeneration and geographic atrophy
Introduction: Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine implicated in pathological changes to the retinal pigment epithelium that are similar to changes in geographic atrophy (GA), an advanced form of age related macular degeneration (AMD). TNF-α also modulates expression of other cytokines including vascular endothelial growth factor (VEGF), leading to choroidal atrophy in models of AMD. The purpose of this study was to investigate systemic TNF-α and VEGF in patients with GA and intermediate AMD (iAMD) compared to controls without AMD.Methods: We examined plasma levels of TNF-α and VEGF in patients with GA, iAMD, and controls without AMD from the University of Colorado AMD registry (2014 to 2021). Cases and controls were characterized by multimodal imaging. TNF-α and VEGF were measured via multiplex immunoassay and data were analyzed using a non-parametric rank based linear regression model fit to plasma biomarkers.Results: There were 97 GA, 199 iAMD patients and 139 controls. TNF-α was significantly increased in GA (Median:9.9pg/ml, IQR:7.3-11.8) compared to iAMD (Median:7.4, IQR:5.3-9.1) and in both GA and iAMD compared to controls (Median:6.4, IQR:5.3-7.8), p<0.01 for all comparisons. VEGF was significantly increased in iAMD (Median:8.9, IQR:4.8-14.3) compared to controls (Median:7.7, IQR:4.6-11.1), p<0.01. There was a significant positive correlation between TNF-α and VEGF in GA (0.46, p<0.01), and iAMD (0.20, p=0.01) with no significant interaction between TNF-α and VEGF in any group.Discussion: These findings suggest TNF-α and VEGF may contribute to systemic inflammatory processes associated with iAMD and GA. TNF-α and VEGF may function as systemic biomarkers for disease development.
- 20 March 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 264, 1-7
Diagnostic Utility of QuantiFERON-Gold Testing in Patients with Ocular Inflammation in a Low-Endemic Tuberculosis Region
- 20 March 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 264, 1-7
Diagnostic Utility of QuantiFERON-Gold Testing in Patients with Ocular Inflammation in a Low-Endemic Tuberculosis Region
- Open Access
- 25 January 2024
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 44 (4) , 545-551
Optic Disc Edema Is an Under-Recognized Feature of Birdshot Chorioretinitis
Background: Optic disc edema is a feature of many ophthalmic and neurologic conditions. It remains an underappreciated feature of birdshot chorioretinitis (BSCR), leading to delay in diagnosis and treatment. The purpose of our study was to identify clinical features that are concomitant with optic disc edema and suggest a diagnosis of BSCR. Methods: Retrospective multicenter case series of 29 patients who were referred to a neuro-ophthalmologist or uveitis specialist for evaluation of disc edema and were ultimately diagnosed with BSCR. Results: Fifty-four eyes of 30 patients, from the practices of 15 uveitis specialists, met the eligibility criteria. In addition to disc edema, concomitant features in all patients included vitritis, chorioretinal lesions, and retinal vasculitis. Visual recovery to 20/40 or better occurred in 26 of 29 patients. Visual acuity remained 20/100 or worse in 2 patients previously diagnosed with idiopathic intracranial hypertension, 1 patient previously diagnosed with optic neuritis, and 1 patient for whom treatment was delayed for years, leading to optic disc atrophy. Conclusions: Optic disc edema is a presenting feature in some cases of BSCR. A diagnosis of BSCR should be considered when disc edema occurs with vitritis, chorioretinal inflammation, and retinal vasculitis. Patients should be referred to a uveitis specialist for treatment.
- 25 January 2024
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 44 (4) , 545-551
Open AccessOptic Disc Edema Is an Under-Recognized Feature of Birdshot Chorioretinitis
Background: Optic disc edema is a feature of many ophthalmic and neurologic conditions. It remains an underappreciated feature of birdshot chorioretinitis (BSCR), leading to delay in diagnosis and treatment. The purpose of our study was to identify clinical features that are concomitant with optic disc edema and suggest a diagnosis of BSCR. Methods: Retrospective multicenter case series of 29 patients who were referred to a neuro-ophthalmologist or uveitis specialist for evaluation of disc edema and were ultimately diagnosed with BSCR. Results: Fifty-four eyes of 30 patients, from the practices of 15 uveitis specialists, met the eligibility criteria. In addition to disc edema, concomitant features in all patients included vitritis, chorioretinal lesions, and retinal vasculitis. Visual recovery to 20/40 or better occurred in 26 of 29 patients. Visual acuity remained 20/100 or worse in 2 patients previously diagnosed with idiopathic intracranial hypertension, 1 patient previously diagnosed with optic neuritis, and 1 patient for whom treatment was delayed for years, leading to optic disc atrophy. Conclusions: Optic disc edema is a presenting feature in some cases of BSCR. A diagnosis of BSCR should be considered when disc edema occurs with vitritis, chorioretinal inflammation, and retinal vasculitis. Patients should be referred to a uveitis specialist for treatment.
- Open Access
- 21 August 2023
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 12 (6) , 3383-3393
Cataract Surgery Outcomes in Patients with Non-ocular Autoimmune Disease
Introduction While phacoemulsification cataract extraction is generally highly effective and safe, patients with a history of uveitis are at higher risk for postoperative complications and often require a modified perioperative medication regimen. No data exists on risks of postoperative complications and persistent anterior uveitis (PAU) in patients with non-ocular autoimmune disease. Methods Medical records were reviewed of patients who underwent phacoemulsification cataract surgery with intraocular lens implantation between January 1, 2014 and December 31, 2019 at the University of Colorado Hospital (UCH) as part of a retrospective cohort study. Exclusion criteria included patient history of ocular inflammation and cataract surgery combined with another intraocular surgery. Patients were only included as having autoimmune disease if the diagnosis was confirmed by a relevant specialist at UCH. Patients with autoimmune disease were then stratified into systemic versus organ-specific autoimmune disease, and patients with systemic autoimmune disease were further stratified into immunosuppressed and not immunosuppressed at the time of cataract surgery. Patients with PAU were identified according to the Standardization of Uveitis Nomenclature Working Group. Data including sex, race/ethnicity, intraoperative cumulative dissipated energy (CDE), and postoperative best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were obtained. Results A total of 422 eyes from 248 patients had confirmed autoimmune disease, compared to a control group of 10,201 eyes. The autoimmune and systemic autoimmune disease groups were not more likely to have postoperative complications or PAU compared to the control group. Immunosuppression status among the systemic autoimmune disease group was also not associated with postoperative complications or PAU. Conclusion Patients with non-ocular autoimmune disease do not appear to be at higher risk for postoperative complications, including worse BCVA or increased rates of IOP elevation and PAU, following phacoemulsification cataract surgery. These patients do not appear to require modification of the typical perioperative medication regimen.
- 21 August 2023
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 12 (6) , 3383-3393
Open AccessCataract Surgery Outcomes in Patients with Non-ocular Autoimmune Disease
Introduction While phacoemulsification cataract extraction is generally highly effective and safe, patients with a history of uveitis are at higher risk for postoperative complications and often require a modified perioperative medication regimen. No data exists on risks of postoperative complications and persistent anterior uveitis (PAU) in patients with non-ocular autoimmune disease. Methods Medical records were reviewed of patients who underwent phacoemulsification cataract surgery with intraocular lens implantation between January 1, 2014 and December 31, 2019 at the University of Colorado Hospital (UCH) as part of a retrospective cohort study. Exclusion criteria included patient history of ocular inflammation and cataract surgery combined with another intraocular surgery. Patients were only included as having autoimmune disease if the diagnosis was confirmed by a relevant specialist at UCH. Patients with autoimmune disease were then stratified into systemic versus organ-specific autoimmune disease, and patients with systemic autoimmune disease were further stratified into immunosuppressed and not immunosuppressed at the time of cataract surgery. Patients with PAU were identified according to the Standardization of Uveitis Nomenclature Working Group. Data including sex, race/ethnicity, intraoperative cumulative dissipated energy (CDE), and postoperative best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were obtained. Results A total of 422 eyes from 248 patients had confirmed autoimmune disease, compared to a control group of 10,201 eyes. The autoimmune and systemic autoimmune disease groups were not more likely to have postoperative complications or PAU compared to the control group. Immunosuppression status among the systemic autoimmune disease group was also not associated with postoperative complications or PAU. Conclusion Patients with non-ocular autoimmune disease do not appear to be at higher risk for postoperative complications, including worse BCVA or increased rates of IOP elevation and PAU, following phacoemulsification cataract surgery. These patients do not appear to require modification of the typical perioperative medication regimen.